SEC Form 4 · accession 0001127602-18-004188

GILEAD SCIENCES, INC. · GILD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP,Corporate &Medical Affairs

Period of report

Feb 1, 2018

Accepted (ET)

Feb 5, 2018 · 9:20 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000882095

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Feb 1, 2018	M	17,250	$40.56	A	62,738	D
Common Stock^F3	Feb 1, 2018	S	9,786	$83.2879	D	52,952	D
Common Stock^F4	Feb 1, 2018	S	15,214	$83.6601	D	37,738	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-qualified Stock Option (Right to Buy)^F2	$40.56	Feb 1, 2018	M	17,250	D	—	Feb 1, 2023	Common Stock	17,250	72,846	D
Non-qualified Stock Option (Right to Buy)^F2	$83.49	Feb 1, 2018	A	62,910	A	—	Feb 1, 2028	Common Stock	62,910	62,910	D

F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F3Sale prices reported for the transactions reported here range from $82.49 to $83.49. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
F4Sale prices reported for the transactions reported here range from $83.49 to $84.04. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.